Skip To Main Content
J. Sabari on Muck Rack

J. Sabari

As seen in: Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with J.

Contact J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

|
By A. Drilon, I. Bergagnini, L. Delasos, J. Sabari, K. Woo
| Annals of Oncology Verified
Background RET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in ALK- and ROS1-rearranged lung cancers, the benefits of pemetrexed-based treatments in patients with RET-rearranged lung cancers relative to other genomic subsets have not previously been explored.
Open in Who Shared Issue with article?

Clinical Outcomes with Pemetrexed-Based Systemic Therapies in RET-rearranged Lung Cancers

|
By A. Drilon, I. Bergagnini, L. Delasos, J. Sabari, K. Woo
| Annals of Oncology Verified
Background RET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in ALK- and ROS1-rearranged lung cancers, the benefits of pemetrexed-based treatments in patients with RET-rearranged lung cancers relative to other genomic subsets have not previously been explored.
Open in Who Shared Issue with article?
See all 2 articles